Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | RYR2 | Q92736 | 6/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206556 | 0.75 | SLC6A4 (0.58) | SLC6A4KCNH2 | |
| SCHEMBL7206520 | 0.73 | SLC6A4 (0.56) | SLC6A4RYR2KCNH2LMNAALDH1A1 | |
| SCHEMBL30016658 | 0.72 | CTSL (0.42) | SLC6A4RYR2KCNH2CTSL | |
| SCHEMBL3115309 | 0.72 | CTSL (0.42) | SLC6A4RYR2KCNH2CTSL | |
| SCHEMBL2881823 | 0.72 | HTR2A (0.53) | SLC6A4PTGDR2ERN1KCNH2ALDH1A1 | |
| SCHEMBL274863 | 0.71 | PTGDR2 (0.48) | SLC6A4PTGDR2ERN1LMNAALDH1A1 | |
| SCHEMBL275629 | 0.71 | LMNA (0.61) | PTGDR2ERN1LMNACYP2A6ALDH1A1 | |
| SCHEMBL2075254 | 0.70 | LMNA (0.62) | SLC6A4PTGDR2ERN1LMNAALDH1A1 | |
| SCHEMBL19865453 | 0.68 | EPAS1 (0.49) | PTGDR2ERN1LMNAGAAKMT2A | |
| SCHEMBL12438312 | 0.68 | MAOB (0.45) | SLC6A4PTGDR2ERN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1313701-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002018333-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | SLC6A4 5/4885PTGDR2 1343/4885ERN1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.